This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
Assessing and Addressing ID/IDA: The Need for Guidance
Assessing and Addressing ID/IDA: The Need for Guidance
Welcome to CME on ReachMD. This episode is part of our MinuteCME curriculum.
Prior to beginning the activity, please be sure to review the faculty and commercial support disclosure statements as well as the learning objectives.
Hello. This is CME on ReachMD, and I’m Dr. Malcolm Munro here with Dr. Arjeme Cavens from Northwestern University, and we’re here to talk about screening and diagnosis of women with iron deficiency and iron deficiency anemia.
So, Arjeme, tell us, what are the guidelines that are provided by the American College for women who are pregnant?
We know that maybe up to 30% or even 50% of women in their first trimester of pregnancy will be iron deficient even if they aren’t anemic. So that gives us some information about these conditions outside of pregnancy. Our guidance really is limited to pregnancy-specific times, and that’s guidance from ACOG who recommends that we screen all pregnant women for anemia, which will consist of a CBC [complete blood count] in the first trimester, and then again repeating that between 24 and 28 weeks. ACOG also recommends that we supplement all pregnant women with low-dose iron. Usually that’s accomplished by just taking a prenatal vitamin, and I think it’s also important to recognize that the definitions of anemia in pregnancy are different than they are outside of pregnancy. So in the first and third trimester, anemia is defined as a hemoglobin of less than 11, and in the second trimester, it’s defined as a hemoglobin of less than 10.5. Really, any patient with anemia in pregnancy should be undergoing further testing for iron deficiency, at least with the ferritin but potentially with other iron studies, and I think it’s important to do that, even if it’s not a patient with a microcytic anemia specifically, because there can be a multitude of micronutrient-deficiencies.
Now, that’s all about pregnancy, and I think what is deficient here is we really don’t have guidelines for screening for iron deficiency or iron deficiency anemia outside of pregnancy, even though we know there can be some adverse outcomes. So we know there can be increased neurodevelopmental disorders, we know that within pregnancy itself there can be an increased risk of low birth rate, preterm delivery, abnormal weight gain, blood transfusions, but we really don’t have good guidance outside of pregnancy of how to screen women pre-conceptually.
So doesn’t that beg the question of routine screening for iron deficiency as a preferential approach than starting with anemia alone?
I think the guidelines aren’t there yet, so certainly an area for further development. This is something that the Women’s Physician Section of the AMA has recognized as concern and is putting forward proposals, but the guidelines aren’t there yet. I think this also highlights what as providers we often focus on for iron deficiency anemia in pregnancy, which is getting a hemoglobin up by the time of delivery, when really we need to minimize the time that that iron deficiency is there throughout the gestation in general.
Well, of course, that brings up the question about the non-pregnant individual prior to pregnancy. And so what does the College do for preconceptual iron deficiency screening or anemia screening even in women who have heavy menstrual bleeding. Is there any guidance there?
So at least at this juncture, there isn’t any screening guidance. I think we are encouraged to be diligent about taking histories and examining our patients to identify patients who might be at risk based on their symptoms or other lifestyle factors or other medical conditions that might put them at risk for iron deficiency, but there really isn’t recommendations for screening, and I think that is an area for future exploration.
Yeah, certainly when you have a disorder that may be present in 50% of women, it would seem that it’s shortsighted not to be evaluating the nonpregnant individual, especially the one whom you know has abnormal uterine bleeding.
Tell us about the issue of disparity and how that influences this entire problem of iron deficiency.
We know that iron deficiency and iron deficiency anemia are more likely to affect women of color, specifically Black and Hispanic women, but also those of lower socioeconomic status, teenage individuals. I do think it’s important to note that in the past, ACOG actually had differential race-based definitions for anemia, and those have since been eliminated. So we need to reiterate that while the thresholds for anemia in pregnancy may be different than those outside of pregnancy, all individuals, regardless of race, age, ethnicity, we all need to be evaluated by the same laboratory standards and therapy recommended for the same treatment goals as well.
Great points. So that’s all the time we have today. Thanks for listening.
You have been listening to CME on ReachMD. This activity is provided by Omnia Education and is part of our MinuteCME curriculum.
To receive your free CME credit, or to download this activity, go to ReachMD.com/Omnia . Thank you for listening.
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Malcolm G. Munro MD, FRCS(c), FACOG
Clinical Professor, Department of Obstetrics & Gynecology
David Geffen School of Medicine at UCLA
Chair, Women’s Health Research Collaborative
Los Angeles, CA
Research: AbbVie, Pharmacosmos
Ownership Interest: Channel Medical, Okon, Gynesonics, U-Vision 360
Patent Holder: Simulators – Assigned to AAGL
Consulting Fees: AbbVie, American Regent
Michael Auerbach, MD
Clinical Professor of Medicine
Georgetown University School of Medicine
Research: Covis Pharma
Arjeme Denise Cavens, MD
Instructor of Obstetrics and Gynecology
Northwestern University Feinberg School of Medicine
No relevant relationships reported.
Michael K. Georgieff, MD
Martin Lenz Harrison Land Grant Chair in Pediatrics
Professor of Pediatrics, Obstetrics and Gynecology, and Developmental Psychology
University of Minnesota Medical School
No relevant relationships reported.
Lee P. Shulman, MD, FACOG, FACMG
The Anna Ross Lapham Professor and Chief
Division of Clinical Genetics
Feinberg School of Medicine of Northwestern University
Consulting Fees: Agile, Aspira, Bayer, Biogix, Celula China, Daiichi Sankyo, Mayne, Organon, Shield
Other: Astellas (DSMB Chair)
Wendy L. Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP
Owner and Family Nurse Practitioner
Wright & Associates Family Healthcare
Consulting Fees: AbbVie, Biohaven, GSK, Idorsia, Merck, Moderna, Pfizer, Sanofi, Seqirus, Shield Therapeutics
- Jennifer Brutsche, RN, BSN, AHA BLS Instructor, has nothing to disclose.
- Cindy Davidson has nothing to disclose.
- Libby Lurwick has nothing to disclose.
- Kate Nagele has nothing to disclose.
- Robert Schneider, MSW, has nothing to disclose.
After participating in this educational activity, participants should be better able to:
- Describe the basics of iron physiology, including its critical role in cellular processes, and impact on growth and development throughout the life span.
- Identify appropriate screening and diagnosis methods throughout the life span.
- Describe the potential impact of iron deficiency (ID)/ ID anemia (IDA) and its treatment, throughout the life span.
- Identify the benefits and disadvantages of using oral iron therapies in the management of iron deficiency (ID) and ID anemia (IDA).
This activity is designed to meet the educational needs of obstetrician-gynecologists, other women’s health HCPs, and primary care physicians.
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until March 31, 2024. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Omnia Education is the leading provider of education for women’s health professionals. Our activities are recognized nationwide for providing credible, relevant, and practical information on issues impacting the female patient. Additionally, our unique focus has transformed the CME learning environment, and our ability to help learners recognize and overcome barriers to optimal performance and optimal patient outcomes has positioned us as a leader in women’s health education.
This activity is supported by an independent educational grant from Shield Therapeutics.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction of this material is not permitted without written permission from the copyright owner.
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.